Foghorn discontinues FHD-286 in AML; prioritizes pipeline and Lilly collaboration

Foghorn Therapeutics Inc.

FHD-286 + decitabine showed objective responses in Phase 1 but efficacy threshold not met for continued standalone development.
Company evaluating partnerships/ISTs for FHD-286; independent development halted.
Priorities: proprietary CBP, EP300, ARID1B programs and Lilly collaboration including SMARCA2 inhibitor FHD-909.
Cash of $267.4M as of Sept 30, 2024; runway into 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.